肝癌临床试验终点及其在循证临床决策中的价值:未解的难题
本文为专家观点文章,指出肝癌临床试验中采用的严格定义与标准(如RECIST缓解、至进展时间、无进展生存期)与真实世界临床实践存在差异,这些终点不能完全替代总生存期作为疗效判断依据;理解这一差异的根源是完善药物活性、毒性和治疗失败定义的前提。
要点
- 临床试验严格入排标准与真实世界患者特征存在差距,影响结果外推。
- RECIST缓解、至进展时间、无进展生存期不能假定为生存的确定性替代终点。
- 疾病进展不等于治疗失败或耐药,临床停药决策需谨慎。
核心结论
- 肝癌临床试验终点与真实世界临床决策之间存在差异,RECIST缓解、至进展时间和无进展生存期不能假定为生存的确定性替代终点。
研究设计与样本
- 本文为专家观点文章,未报告系统检索范围或样本量。
主要发现
- 临床试验目标人群定义狭窄,以评估药物活性和毒性并最终证明生存获益为目标。
- 真实世界患者可能不符合临床试验严格的入排标准。
- 临床实践中对药物活性的评估可能不同,疾病轻微进展时可能不遵循试验中进展即停药的常规策略。
- RECIST缓解、至进展时间和无进展生存期不能完全提供信息,不能假定为生存的确定性替代终点;生存是治疗性癌症研究中最难的终点。
关键数值与推荐
- 未报告具体数值、阈值或推荐条款。
临床怎么用
- 临床解读肝癌临床试验结果时应考虑入排标准与真实世界患者的差异。
- 不应将RECIST缓解、至进展时间或无进展生存期直接等同于生存获益。
- 疾病进展登记不一定反映治疗失败或耐药,临床决策需结合具体情况。
局限性
- 本文为专家观点,未提供系统综述或原始研究数据。
- 未报告具体样本量、效应量或统计检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The design and execution of clinical trials relies on strict definitions and criteria to avoid heterogeneous decisions by investigators at different sites. Ideally, definitions and decision making in clinical practice should mimic those implemented in trials, but this is not the case. Target populations are narrowly defined in trials, with the goal of evaluating activity and toxicity, and ultimately, demonstrating a survival benefit. In real-world practice, patients may not fit into the stringent inclusion/exclusion criteria of clinical trials. The evaluation of activity may also differ and the common policy to stop therapy upon progression may not be followed if progression is minor. Indeed, registration of progression may not reflect treatment failure or resistance. Parameters such as response according to RECIST criteria, time to progression and progression-free survival are not fully informative and cannot be assumed as a definitive surrogate for survival, which is the hardest endpoint in therapeutic cancer studies. This difference is because of the varying methods used to evaluate drug activity and tumour evolution, which ultimately dictates patient outcome. This expert opinion exposes the current discrepancies between research trials and clinical practice. Understanding the origin and limitations of such a conundrum should be the first step in refining the criteria that define drug activity, toxicity and treatment failure. Otherwise, evidence-based clinical practice and precision oncology will be an unattainable reality.
引用
- Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. J Hepatol. 2021. PMID: 33556420. doi:10.1016/j.jhep.2021.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。